Heart drug trial offers new hope for inherited heart condition
NCT ID NCT04706429
Summary
This study tested whether a drug called trientine, already used for a different copper-related disease, could help people with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens. For 12 months, 154 adult patients with HCM received either trientine or a placebo pill to see if it could reduce heart thickening, improve exercise ability, and help heart function. The goal was to find a new treatment that could control this inherited heart disease, for which there are currently no therapies that change its long-term course.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Liverpool Heart and Chester Hospital NHS Foundation Trust
Liverpool, L14 3PE, United Kingdom
-
Manchester University NHS Foundation Trust
Manchester, M23 9LT, United Kingdom
-
NHS Grampian
Aberdeen, AB25 2ZN, United Kingdom
-
Northumbria Healthcare NHS Foundation Trust
North Shields, NE29 8NH, United Kingdom
-
Oxford University Hospitals NHS Foundation Trust
Oxford, OX3 9DU, United Kingdom
-
Royal Brompton and Harefield NHS Foundation Trust
London, SW3 6NP, United Kingdom
-
University Hospitals of Leicester NHS Foundation Trust
Leicester, LE3 9QP, United Kingdom
Conditions
Explore the condition pages connected to this study.